Gastric Cancer Incidence Increasing in Younger Population in Latin America

Article

A new study found an upward trend over the last 12 years of cases of gastrointestinal cancer in young patients in Latin America.

The incidence of gastric cancer in younger people increased substantially over a 12-year period in Latin America, according to a new study. The increase was seen primarily in young women, who often presented with more advanced disease.

“Gastric cancer has been considered a disease of the older population worldwide,” wrote study authors led by Germán Calderillo-Ruiz, MD, of the National Cancer Institute in Tlalpan, Mexico. He presented results of the new retrospective, observational study at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2019, held July 3-6 in Barcelona, Spain.

The study included a total of 2,022 patients with gastric adenocarcinoma, treated between 2004 and 2016 at INCAN Mexico. Of that total, 290 patients (14%) were 40 years of age or under; of those younger patients, 54% were women. The mean age of both women and men among the younger patients was 34.6 years. The study found a 120% increase over the 12-year study period of patients aged 40 years or younger.

Most of the primary tumors in this younger cohort were gastric (93%), followed by the esophagogastric junction (7%). Most patients presented with stage IV disease (76%), followed by 16% with locally advanced disease and 8% with stage I–III gastric cancer.

Compared with men, women presented with higher rates of poor prognostic factors. A total of 68% of women had diffuse-type histology compared with 32% of men (P = 0.127); more women had ring-seal cells (76% vs 69%; P = 0.049), poorly differentiated gastric cancer (89% vs 84%; P = 0.014), and were more likely to present with stage IV disease (59% vs 41%; P = 0.011).

The median overall survival (OS) for the women in the study was 7 months, compared with 8 months for men, for a hazard ratio of 1.29 (95% CI, 1.05–1.65; P = 0.030). The median OS was longer for patients with esophagogastric junction tumors than with gastric tumors.

A multivariate analysis found that gender was an independent predictor of overall survival, with an HR of 1.29 (95% CI, 1.01–1.65; P = 0.038). Primary tumor site and clinical stage at presentation were also independent predictors of survival, while histology was not significantly associated.

“The lack of financial resources may impact on women’s behaviour of delaying pursuit of medical care when gastric symptoms appear,” Calderillo-Ruiz said. “We hope this research will encourage clinicians and patients to be more aware of the risk of gastric cancer in younger people and, in particular, to encourage women with gastric symptoms to seek medical help sooner.”

Rodrigo Dienstmann, MD, of Vall d’Hebron Institute of Oncology in Barcelona, who commented on the study for ESMO, noted the combination of genetic and environmental factors that go into the development of gastric cancer.

“We cannot change the genetic factors, but we can act on the unhealthy diet, obesity, and untreated Helicobacter pylori infection which increase the risk of gastric cancer,” he said. “Helicobacter infection can cause chronic inflammation and lesions that are precursors to gastric cancer but, once diagnosed, can be cured with a combination of antibiotics and drugs to reduce stomach acid.”

He stressed that younger people who regularly experience heartburn or other gastric symptoms should consult a physician, while clinicians should be aware that gastric cancer is not uncommon among younger individuals.

Recent Videos
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Related Content